Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Get away from the Tedious Drudgery: Go into Business Today! - 2Instructions to Pick the Best Album Rates for Your Investment funds
- 3Top Pastry: What's Your Sweet Treat of Decision?
- 4In Antarctica, photos show a remote area teeming with life amid growing risks from climate change
- 5Journey Travel Objections for Your Next Experience
- ‘Raising 10 red flags’: Is Israel’s army exhausted?
- January full moon wows skywatchers with a striking 'Wolf Supermoon' (photos)
- 6 Solid Moving Administrations for a Calm Movement
- The Beginning Of The End For Fossil Fuels Can Start In Colombia
- Must-Have Wellness Gear: What to Purchase for Successful Exercises
- Eurovision Song Contest changes voting rules after controversial allegations against Israel
- German politician urges more face-to-face interaction in digital age
- PHOTO ESSAY: Scientists trying to unravel one of the body's biggest mysteries
- Step by step instructions to Boost the Eco-friendliness of Your Smash 1500.
